In summary, we provide evidence for the presence of infectious prions in the brains of conventional prion-assay-negative deer orally exposed 19 months earlier to urine and feces from CWD-infected donor deer.
In vitro prion replication assays report a relatively low efficiency of CWD PrPSc-directed conversion of human PrPc to PrPSc (30 ), and transgenic mice overexpressing human PrPc are resistant to CWD infection (31 ); these findings indicate low zoonotic potential.
A structure activity relationship is described for a series of peptides which were synthesised and tested for their activity against two prion disease model assays, an in vitro cellular assay and an in vitro anti-aggregation polymerisation assay.
Using an in vitro prion protein conversion assay, which has been previously used to assess TSE species barriers and, in our study appears to recollect known species barriers in mice, we assessed the potential transmissibility of TSEs to BHS.
Prion infection was assayed by the presence of PrPSc by cell blot assay.
To study the correlation between PrPSc loads and titers of infectious prions, we assayed prion titers of muscle and spleen by bioassay.
The respective advantages and disadvantages of end-point titration and lag time assays are well known from assays of prion infection in vivo.
The α1-ACT ELISA assay predicted prion infection with excellent sensitivity and specificity.
It is possible that the human genes that do not report in this assay have prion strain-specific roles or require allele specific modifications in cells to alter the phenotype.
To date, all validated laboratory assays for prion diseases rely on the immunochemical detection of PrPSc.
In our hands, the adequate amplification of soil-bound prions for the Elispot assay required less than 4 weeks.
